uniQure saw a dramatic pre-market gain of 67.5% after announcing that the U.S. Food and Drug Administration told the company, following a recent Type B meeting, that three-year results from its Phase I/II clinical trial of AMT-130 would be acceptable as the primary foundation for a Biologics License Application (BLA) seeking accelerated approval for Huntington’s disease.
The company said it intends to submit the BLA in the third quarter of 2026. According to uniQure, the FDA indicated it would work as expeditiously as possible to come to agreement on the design of the required confirmatory study prior to the BLA submission.
This development reverses a damaging regulatory setback from November 2025, when the FDA unexpectedly withdrew earlier guidance and rejected the use of an external control group as the main efficacy comparator. That November reversal had driven a sharp decline in the stock.
Executives at uniQure framed the FDA response as a restoration of the accelerated approval pathway investors had assumed would be available. CEO Matt Kapusta described the decision as "the outcome we have worked toward throughout our continued regulatory engagement with FDA."
The announcement lifted not only uniQure shares but also those of ClearPoint Neuro, whose navigation system is used to administer AMT-130, reflecting the interdependence of device and drug delivery partners on procedural and regulatory progress.
The move in uniQure stock was notably company-specific. The broader market provided little support: the Nasdaq fell 1.2% and the S&P 500 slipped 0.6%, underlining that the stock’s surge was driven by this regulatory development rather than by wider sector or macro momentum.
AMT-130 had previously held both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, designations that had signaled the agency’s recognition of the therapy’s potential in a condition that currently lacks disease-modifying treatments.
Market reaction was sizable: the pre-market rally pushed the stock toward $45.20, well above the prior closing price of $26.99 and recovering significant ground from a 52-week low of $8.73 reached earlier this year.
What this means
- The FDA’s agreement that three-year Phase I/II data can underpin an accelerated-approval BLA reopens a pathway that had been narrowed by the agency’s November 2025 clarification.
- uniQure plans to file a BLA in Q3 2026, and the FDA has committed to working quickly to align on the confirmatory study design prior to that submission.
- Related supply-chain and device partners, notably ClearPoint Neuro, saw positive share movement tied to the procedural implications of the announcement.
Market context
Despite the strong single-company reaction, major indices moved lower on the day, signaling that uniQure’s rally was driven by the regulatory outcome rather than broader investor sentiment in biotech or the wider market.